LAUSR

507Background: Metastatic Pancreatic Cancer (MPC) is associated with an extremely high mortality. Current NCCN guidelines recommend systemic therapy, as it is superior to best supportive care. Undertreatment of MPC continues to be an issue. Recent treatment and survival data of MPC in Veterans’ Affairs’ (VA) hospitals have not been published. The relationship between treatment and American College of Surgeons’ (ACS) Committee on Cancer (CoC) accreditation has not been studied. Methods: Nationwide data from the National Veterans Affairs Cancer Cube Registry was analyzes. 7,585 patients were diagnosed with MPC between 2000 and 2017. Systemic therapy was only looked at as it is the standard of treatment for MPC. CoC accreditation of each VA hospital was obtained using the ACS website. Local IRB approval was obtained. Results: MPC constitutes 52.44% of pancreatic cancer diagnosed (7,585 out of 14,464 cases). The near totality were men (97.43%). The 60-70 age group constitutes the most common age at diagnosis ...